MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual MeetingGlobeNewsWire • 04/21/23
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational ResultsGlobeNewsWire • 03/14/23
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022GlobeNewsWire • 12/08/22
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/10/22
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual CongressGlobeNewsWire • 10/04/22
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)GlobeNewsWire • 10/01/22
MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish GovernmentGlobeNewsWire • 09/16/22
MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/11/22
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing FacilitiesGlobeNewsWire • 08/03/22
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to GlobeNewsWire • 06/28/22
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/12/22
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingGlobeNewsWire • 05/04/22
MeiraGTx Holdings PLC (MGTX) Stock Jumps 6.5%: Will It Continue to Soar?Zacks Investment Research • 03/30/22
MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/10/22
MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational ResultsGlobeNewsWire • 03/10/22
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth SymptomBenzinga • 12/07/21
MeiraGTx Announces Positive Preliminary Data from the AQUAx Phase 1 Clinical Trial of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewsWire • 12/07/21
MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene RegulationGlobeNewsWire • 11/29/21
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/10/21